Polly Gregor Q Daisy Huang Humilidad F Gallardo Teresa S Rasalan Michael J Morris
10.1016/j.clgc.2011.12.002
Clin Genitourin Cancer
2012 Jun;10(2):126-9.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/22284755/
Adenocarcinoma / immunology Antigens, Neoplasm / metabolism Glutamate Carboxypeptidase II / metabolism Melanoma / immunology Neoplasms, Second Primary / immunology Prostatic Neoplasms / immunology Skin Neoplasms / immunology
Adenocarcinoma / immunology Antigens, Neoplasm / metabolism Glutamate Carboxypeptidase II / metabolism Melanoma / immunology Neoplasms, Second Primary / immunology Prostatic Neoplasms / immunology Skin Neoplasms / immunology Case Reports Adenocarcinoma / blood Adenocarcinoma / drug therapy Aged, 80 and over Antibodies, Neoplasm / blood Antigens, Neoplasm / immunology Antineoplastic Agents / therapeutic use Biomarkers, Tumor / blood Combined Modality Therapy Docetaxel Fatal Outcome Glutamate Carboxypeptidase II / immunology Humans Immunotherapy Male Melanoma / blood Melanoma / therapy Neoplasm Metastasis Neoplasms, Second Primary / blood Neoplasms, Second Primary / drug therapy Prostate-Specific Antigen / blood Prostatic Neoplasms / blood Prostatic Neoplasms / drug therapy Skin Neoplasms / blood Skin Neoplasms / therapy Taxoids / therapeutic use Antibodies, Neoplasm Antigens, Neoplasm Antineoplastic Agents Biomarkers, Tumor Taxoids Docetaxel Glutamate Carboxypeptidase II Prostate-Specific Antigen
PMC3358358
22284755
A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen
2012